NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). Shareholders who purchased shares of NUTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/nutex-health-inc-loss-submission-form/?id=169642&from=3 CLASS PERIOD: August 8, ...

Core Insights - Acadia Healthcare is one of the largest operators of behavioral health facilities in the U.S. [1] - The company is participating in the 2025 Jefferies Healthcare Services Conference, indicating its active engagement with investors and stakeholders [1] Company Announcements - Acadia Healthcare issued an 8-K filing, which includes important announcements regarding recent activism directed at the company [2] - The CEO of Acadia Healthcare, Hunter, is addressing the activism and related announcements during the conference [2]

Core Insights - Elevance Health, Inc. is a prominent healthcare company with a market capitalization of $71.7 billion, serving approximately 46.8 million members through various health plans and services [1] Financial Performance - The company is set to announce its fiscal Q3 earnings for 2025 on October 21st, with analysts projecting a profit of $5.01 per share, representing a 40.1% decline from $8.37 per share in the same quarter last year [2] - For the current year, analysts expect Elevance Health to report an EPS of $29.89, down 9.5% from $33.04 in fiscal 2024, but anticipate a rebound in FY2026 with a projected EPS of $30.96, reflecting a 3.6% year-over-year increase [3] Stock Performance - Shares of Elevance Health have decreased by 38.8% over the past 52 weeks, significantly underperforming compared to the S&P 500 Index, which has increased by 15.6%, and the Health Care Select Sector SPDR Fund, which has seen an 11.5% loss during the same period [4] Market Sentiment - Wall Street analysts maintain a "Moderate Buy" rating for Elevance Health, with 13 out of 21 analysts recommending "Strong Buy," one suggesting "Moderate Buy," six indicating "Hold," and one advising "Strong Sell." The mean price target for the stock is $359.06, suggesting a potential upside of 12.7% from current levels [6] Regulatory Environment - On September 25, shares of Elevance Health fell by 3% following the U.S. Commerce Department's initiation of a national security investigation into medical equipment imports, which could lead to new tariffs and create uncertainty within the healthcare sector [5]

Group 1: ModivCare (NASDAQ: MODV) - ModivCare is undergoing a significant restructuring process following a Chapter 11 bankruptcy filing, focusing on debt reduction and capital stabilization [2][3] - The restructuring has the support of over 90% of First Lien and 70% of Second Lien Lenders, with the company set to receive $100 million in debtor-in-possession financing and maintain over $100 million in liquidity while reducing debt by $1.1 billion [3] - Despite challenges such as potential delisting and operational hurdles, analysts are observing whether these efforts could lead to recovery or make ModivCare an acquisition target, with the stock priced at $0.18, having corrected almost 100% year to date [4] Group 2: Ceragon Networks (NASDAQ: CRNT) - Ceragon Networks has experienced bearish momentum in 2025, with the stock dropping almost 50% year to date, trading at $2.37 [5] - The company generates steady revenue and is involved in modernizing communications networks, although recent statutory profit was reduced by $5.3 million due to unusual one-off items, indicating potential for profit growth if these items do not recur [8] - Ceragon faces challenges in India related to carrier financing and logistics, while North America shows strong performance; management is focused on technology leadership, validated by a recent U.S. tier 1 win expected to ramp in 2026, but profitability issues and competitive pressures remain concerns [9]

Market Overview - The market is experiencing a broad rally, although the NASDAQ is lagging behind [1] - There are concerns regarding the sustainability of the rally without big tech leading the way [1][2] Sector Performance - Technology sector continues to perform well, with a robust earnings outlook despite concerns over valuations and returns on capital [3] - Financials, utilities, and healthcare are preferred sectors, with expectations of increasing prices in healthcare due to inflation [3] - The Russell 2000 index has seen a decline of 1.4%, reflecting a rethink of expectations regarding Federal Reserve interest rate cuts [4] Economic Indicators - The core PCE inflation rate is at 2.9%, remaining above the Federal Reserve's target for over four years, indicating persistent inflationary pressures [5] - Recent economic data shows strong spending numbers, but there are concerns about whether Fed cuts will lead to lower mortgage rates [8] Interest Rates and Federal Reserve Actions - The expectation is for the 10-year yield to stabilize around 4.25% in the coming year, with potential for slight decreases [9] - There is a belief that the Federal Reserve will cut rates, but the yield curve may steepen, which is favorable for financials and banks [10] Tariff Impact on Companies - U.S. companies, particularly in the S&P 500, are well-managed and capable of navigating challenges posed by new tariffs [14] - The tech sector is expected to see winners emerge, but there is caution that enthusiasm for certain names may be overblown [15]

Company Overview - Cardinal Health is one of the world's largest healthcare services and products providers, operating across various segments including Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution [12] - The company serves nearly 90% of U.S. hospitals and delivers over 43,000 pharmaceutical shipments daily [12] - Cardinal Health manages a broad portfolio of medical, surgical, and laboratory products, and operates nearly 130 nuclear pharmacies and 30 PET cyclotron facilities [12] Investment Ratings - Cardinal Health has a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong potential for growth [13][14] - The company is particularly appealing for growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 14.2% for the current fiscal year [13] Earnings Estimates - Seven analysts have revised their earnings estimates upwards in the last 60 days for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.20 to $9.41 per share [13] - Cardinal Health boasts an average earnings surprise of +9.2%, further indicating its strong performance potential [13]

Core Insights - Bretton Fund's second quarter 2025 performance was 2.70%, underperforming the S&P 500 Index which returned 10.94% [1] - The fund's underperformance was attributed to a focus on fundamentals rather than market sentiment, particularly in light of the president's easing of tariff threats [1] - Notable underperformers included Berkshire Hathaway and AutoZone, which were categorized as "safe stocks" rather than due to operational issues [1] Company Highlights: UnitedHealth Group Incorporated (NYSE:UNH) - UnitedHealth Group's stock experienced a significant decline of 39.88% over the past 52 weeks, despite a one-month return of 14.31% [2] - As of September 25, 2025, UnitedHealth Group's stock closed at $345.56, with a market capitalization of $312.965 billion [2] - The fund reported that UnitedHealth Group's stock drop contributed to a 2.0% loss for the fund this quarter, indicating a substantial impact on overall performance [3] Financial Performance - UnitedHealth Group reported revenues of nearly $112 billion for the second quarter of 2025, reflecting a 13% increase compared to the same quarter the previous year [4] - The company ranked 18th among the 30 Most Popular Stocks Among Hedge Funds, with 159 hedge fund portfolios holding its stock at the end of the second quarter, up from 139 in the previous quarter [4] Investment Perspective - While UnitedHealth Group is recognized for its potential as an investment, the analysis suggests that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Points - Aveanna Healthcare Holdings Inc. will participate in the Deutsche Bank Annual Leveraged Finance Conference on October 15, 2025, in Austin, TX, and will host one-on-one investor meetings that day [1] Company Overview - Aveanna Healthcare is headquartered in Atlanta, Georgia, and operates in 38 states, offering a wide range of pediatric and adult healthcare services, including nursing, rehabilitation, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill patients, home health and hospice services, and delivery of enteral nutrition [2] - The company provides case management services to assist families and patients in coordinating services among insurers, physicians, hospitals, and other healthcare providers [2] - Aveanna also offers respite healthcare services, which are temporary care services provided to relieve the patient's normal caregiver, aiming to provide high-quality, lower-cost alternatives to prolonged hospitalization [2]

Core Insights - Bethany Children's Health Center has partnered with Commure to reduce clinician documentation load and enhance productivity [1][4] - The integration of Commure's platform will utilize Ambient AI and Agents to allow clinicians to focus more on patient care [2][3] - Commure's technology processes over 20 million clinician appointments annually, showcasing its capability and reliability [3] Company Overview - Bethany Children's Health Center is a MEDITECH-powered pediatric rehabilitation hospital serving children with complex medical needs [1] - Commure specializes in AI infrastructure for enterprise health systems, focusing on ambient intelligence and revenue cycle automation [4][5] Partnership Details - The partnership aims to customize the platform to meet the specific needs of Bethany Children's, enhancing both accuracy and reliability [3] - Commure's CEO emphasized the shared commitment to reducing administrative burdens, allowing clinicians to spend more time with patients [4] Market Demand - The integration reflects a growing demand for scalable solutions that ensure clinical excellence and operational sustainability across various care settings [4]

Summary of Conference Call Notes Industry Overview - **Industry**: Healthcare Services and Medical Devices - **Period**: 1H25 - **Key Challenges**: Ongoing policy headwinds including DRG/DIP reforms, reimbursement controls, and VBP impacting revenue and profitability across the sector [1][2][3][7] Core Insights - **Mixed Results**: The Medtech & Services sector reported soft results in 1H25, aligning with expectations due to policy challenges, but investor sentiment is improving due to a more favorable policy outlook [1][2] - **Recovery Expectations**: A clearer recovery is anticipated in 2H25, driven by easier comparisons and normalization of hospital activities [2] - **Reimbursement Pressures**: Reimbursement controls and DRG/DIP pressures are expected to persist, but an increase in patient visits may lead to top-line recovery [2][7] Company-Specific Highlights - **AngelAlign**: - Positive outlook with raised full-year case volume guidance to 490k-500k, indicating a growth of +36% to +39% year-on-year [11] - Overseas case volume growth of +103% year-on-year, but near-term profitability is under pressure due to increased investments [8][11] - **Kangji Medical**: - Reported +8.3% year-on-year sales growth, supported by new product ramp-up and overseas expansion (+27.7% year-on-year) [3] - Anticipates volume recovery as VBP coverage expands [8] - **AK Medical**: - Flat operating profit with modest revenue growth (+5.6% year-on-year) due to margin pressure from VBP-affected products [3] - Unchanged FY25 earnings guidance [11] - **Shandong Weigao**: - Missed expectations with flat revenue (+0.1% year-on-year) and a 9% year-on-year decline in net profit due to VBP impact [3] - **Hygeia**: - Experienced a 34.5% year-on-year decline in adjusted net profit, driven by DRG/DIP reforms [7] - Focus on operational efficiency and cash flow resilience [10] - **Jinxin Fertility**: - Significant net loss in 1H25 due to one-off impairments, but expects a sequential recovery in cycles supported by increased volumes in July/August [9][11] Market Dynamics - **Pricing Pressure**: VBP continues to exert pressure on margins, but is seen as manageable for leading domestic players [8] - **Global Expansion**: Companies are increasingly focusing on global expansion, with varying success across the sector [8] - **Surgical Robots**: Moderate recovery in domestic procurement with increased globalization efforts from domestic players [8] Financial Performance Metrics - **Kangji Medical**: Net profit declined 18.5% year-on-year due to lower interest income and losses from its surgical robot unit [3] - **Hygeia**: Improved operating cash flow by 29.9% year-on-year [10] - **Gushengtang**: Delivered resilient margins and doubled operating cash flow, guiding for 10-15% revenue growth for FY25 [10] M&A Activity - **Divergent Attitudes**: Companies exhibit varied attitudes towards M&A, with some like Hygeia actively seeking acquisitions while others remain cautious [10] Guidance and Future Outlook - **Overall Sector Guidance**: A more sustainable valuation recovery will require fundamental improvements across the Medtech and Services sectors [2] - **Key Risks**: Include pricing pressure from weak macro consumption trends, regulatory headwinds, and competition in the domestic market [13][15][19] This summary encapsulates the key points from the conference call, highlighting the challenges and opportunities within the healthcare services and medical devices industry.